OBJECTIVE: We previously demonstrated a widening in the mortality gap between subjects with rheumatoid arthritis (RA) and the general population. We examined the contribution of rheumatoid factor (RF) positivity on overall mortality trends and cause-specific mortality. METHODS: A population-based RA incidence cohort (1955-1995, and aged >or= 18 yrs) was followed longitudinally until death or January 1, 2006. The underlying cause of death as coded from national mortality statistics and grouped according to ICD-9/10 chapters was used to define cause-specific mortality. Expected cause-specific mortality rates were estimated by applying the age-, sex-, and calendar-year-specific mortality rates from the general population to the RA cohort. Poisson regression was used to model the observed overall and cause-specific mortality rates according to RF status, accounting for age, sex, disease duration, and calendar year. RESULTS: A cohort of 603 subjects (73% female; mean age 58 yrs) with RA was followed for a mean of 16 years, during which 398 died. Estimated survival at 30 years after RA incidence was 26.0% in RF+ RA subjects compared to 36.0% expected (p < 0.001), while in RF- RA subjects, estimated survival was 29.1% compared to 28.3% expected (p = 0.9). The difference between the observed and the expected mortality in the RF+ RA subjects increased over time, resulting in a widening of the mortality gap, while among RF- RA subjects, observed mortality was very similar to the expected mortality over the entire time period. Among RF+ RA subjects, cause-specific mortality was higher than expected for cardiovascular [relative risk (RR) 1.50; 95% confidence interval (CI) 1.22, 1.83] and respiratory diseases [RR 3.49; 95% CI 2.51, 4.72]. Among RF- RA subjects, no significant differences were found between observed and expected cause-specific mortality. CONCLUSION: The widening in the mortality gap between RA subjects and the general population is confined to RF+ RA subjects and largely driven by cardiovascular and respiratory deaths.
OBJECTIVE: We previously demonstrated a widening in the mortality gap between subjects with rheumatoid arthritis (RA) and the general population. We examined the contribution of rheumatoid factor (RF) positivity on overall mortality trends and cause-specific mortality. METHODS: A population-based RA incidence cohort (1955-1995, and aged >or= 18 yrs) was followed longitudinally until death or January 1, 2006. The underlying cause of death as coded from national mortality statistics and grouped according to ICD-9/10 chapters was used to define cause-specific mortality. Expected cause-specific mortality rates were estimated by applying the age-, sex-, and calendar-year-specific mortality rates from the general population to the RA cohort. Poisson regression was used to model the observed overall and cause-specific mortality rates according to RF status, accounting for age, sex, disease duration, and calendar year. RESULTS: A cohort of 603 subjects (73% female; mean age 58 yrs) with RA was followed for a mean of 16 years, during which 398 died. Estimated survival at 30 years after RA incidence was 26.0% in RF+ RA subjects compared to 36.0% expected (p < 0.001), while in RF- RA subjects, estimated survival was 29.1% compared to 28.3% expected (p = 0.9). The difference between the observed and the expected mortality in the RF+ RA subjects increased over time, resulting in a widening of the mortality gap, while among RF- RA subjects, observed mortality was very similar to the expected mortality over the entire time period. Among RF+ RA subjects, cause-specific mortality was higher than expected for cardiovascular [relative risk (RR) 1.50; 95% confidence interval (CI) 1.22, 1.83] and respiratory diseases [RR 3.49; 95% CI 2.51, 4.72]. Among RF- RA subjects, no significant differences were found between observed and expected cause-specific mortality. CONCLUSION: The widening in the mortality gap between RA subjects and the general population is confined to RF+ RA subjects and largely driven by cardiovascular and respiratory deaths.
Authors: F C Arnett; S M Edworthy; D A Bloch; D J McShane; J F Fries; N S Cooper; L A Healey; S R Kaplan; M H Liang; H S Luthra Journal: Arthritis Rheum Date: 1988-03
Authors: Elaine Thomas; Deborah P M Symmons; David H Brewster; Roger J Black; Gary J Macfarlane Journal: J Rheumatol Date: 2003-05 Impact factor: 4.666
Authors: Hilal Maradit Kremers; Michelle Bidaut-Russell; Christopher G Scott; Megan S Reinalda; Alan R Zinsmeister; Sherine E Gabriel Journal: J Rheumatol Date: 2003-09 Impact factor: 4.666
Authors: F Wolfe; D M Mitchell; J T Sibley; J F Fries; D A Bloch; C A Williams; P W Spitz; M Haga; S M Kleinheksel; M A Cathey Journal: Arthritis Rheum Date: 1994-04
Authors: Sherine E Gabriel; Cynthia S Crowson; Hilal Maradit Kremers; Michele F Doran; Carl Turesson; W Michael O'Fallon; Eric L Matteson Journal: Arthritis Rheum Date: 2003-01
Authors: Gregory D Summers; Giorgos S Metsios; Antonios Stavropoulos-Kalinoglou; George D Kitas Journal: Nat Rev Rheumatol Date: 2010-07-20 Impact factor: 20.543
Authors: Jeffrey A Sparks; Shun-Chiao Chang; Katherine P Liao; Bing Lu; Alexander R Fine; Daniel H Solomon; Karen H Costenbader; Elizabeth W Karlson Journal: Arthritis Care Res (Hoboken) Date: 2016-06 Impact factor: 4.794
Authors: Aaron D Crowson; Robert C Colligan; Eric L Matteson; John M Davis; Cynthia S Crowson Journal: J Rheumatol Date: 2016-11-15 Impact factor: 4.666
Authors: Hilal Maradit Kremers; Elena Myasoedova; Cynthia S Crowson; Guergana Savova; Sherine E Gabriel; Eric L Matteson Journal: Rheumatology (Oxford) Date: 2010-07-13 Impact factor: 7.580
Authors: Dimitrios A Pappas; Jon T Giles; Geoffrey Connors; Noah Lechtzin; Joan M Bathon; Sonye K Danoff Journal: Arthritis Res Ther Date: 2010-05-27 Impact factor: 5.156
Authors: Jon T Giles; Sonye K Danoff; Jeremy Sokolove; Catriona A Wagner; Robert Winchester; Dimitrios A Pappas; Stanley Siegelman; Geoff Connors; William H Robinson; Joan M Bathon Journal: Ann Rheum Dis Date: 2013-05-28 Impact factor: 19.103